Verification of the Vitek Reveal System for Direct Antimicrobial Susceptibility Testing in Gram-Negative Positive Blood Cultures

Overview

Journal Antibiotics (Basel)

Specialty Pharmacology

Date 2024 Nov 27

PMID 39596752

Authors

Giulia Menchinelli

Damiano Squitieri

Carlotta Magri

Flavio De Maio

Tiziana DInzeo

Margherita Cacaci

Giulia De Angelis

Maurizio Sanguinetti

Brunella Posteraro

Affiliations

Soon will be listed here.

Abstract

: The International Organization for Standardization (ISO) 20776-2:2021, which replaces ISO 20776-2:2007, focuses solely on the performance of antimicrobial susceptibility testing (AST) assays, emphasizing the ISO 20776-1 broth microdilution method as the reference standard. Consequently, categorical agreement (CA) and associated errors should not be applied. We verified the Vitek Reveal AST assay according to both ISO 20776-2:2021 and ISO 20776-2:2007 criteria. : Samples from 100 simulated and clinical Gram-negative (GN) positive blood cultures (PBCs) were tested at a large teaching hospital. The simulated GN-PBCs were obtained from a hospital collection of isolates selected to represent diverse antimicrobial resistance profiles. The Reveal assay results were compared with those from the reference assay, and the time to result (TTR) for the Reveal assay was calculated. : The essential agreement rates were 96.1% (816/849) for simulated and 98.8% (929/940) for clinical GN-PBC samples. The bias values were -3.1 for simulated and -11.0 for clinical samples. The CA rates were 97.7% (808/827) for simulated and 99.2% (924/931) for clinical samples. The mean TTR ± SD (hours) for resistant organisms was significantly lower (4.40 ± 1.15) than that for susceptible, increased exposure (5.52 ± 0.48) and susceptible (5.54 ± 0.49) organisms. : Our findings reinforce the potential of the Reveal assay as a valuable tool and support its implementation in clinical microbiology laboratories.

References

Berinson B, Both A, Berneking L, Christner M, Lutgehetmann M, Aepfelbacher M . Usefulness of BioFire FilmArray BCID2 for Blood Culture Processing in Clinical Practice. J Clin Microbiol. 2021; 59(8):e0054321. PMC: 8373244. DOI: 10.1128/JCM.00543-21. View

Coppi M, Antonelli A, Giani T, Spanu T, Liotti F, Fontana C . Multicenter evaluation of the RAPIDEC® CARBA NP test for rapid screening of carbapenemase-producing Enterobacteriaceae and Gram-negative nonfermenters from clinical specimens. Diagn Microbiol Infect Dis. 2017; 88(3):207-213. DOI: 10.1016/j.diagmicrobio.2017.04.009. View

. Global burden of bacterial antimicrobial resistance 1990-2021: a systematic analysis with forecasts to 2050. Lancet. 2024; 404(10459):1199-1226. PMC: 11718157. DOI: 10.1016/S0140-6736(24)01867-1. View

Antonelli A, Cuffari S, Casciato B, Giani T, Rossolini G . Evaluation of the Vitek® Reveal™ system for rapid antimicrobial susceptibility testing of Gram-negative pathogens, including ESBL, CRE and CRAB, from positive blood cultures. Diagn Microbiol Infect Dis. 2024; 110(4):116503. DOI: 10.1016/j.diagmicrobio.2024.116503. View

De Angelis G, Posteraro B, Menchinelli G, Liotti F, Spanu T, Sanguinetti M . Antimicrobial susceptibility testing of pathogens isolated from blood culture: a performance comparison of Accelerate Pheno™ and VITEK® 2 systems with the broth microdilution method. J Antimicrob Chemother. 2019; 74(Suppl 1):i24-i31. PMC: 6382034. DOI: 10.1093/jac/dky532. View

Menchinelli G, Liotti F, Giordano L, De Angelis G, Sanguinetti M, Spanu T . Efficient Inactivation of Clinically Relevant Antimicrobial Drug Concentrations by BacT/Alert or Bactec Resin-Containing Media in Simulated Adult Blood Cultures. Antimicrob Agents Chemother. 2019; 63(7). PMC: 6591622. DOI: 10.1128/AAC.00420-19. View

Bianco G, Boattini M, Comini S, Bondi A, Curtoni A, Piccinini G . Detection of volatile organic compounds as new paradigm to accelerate antimicrobial susceptibility testing: performance evaluation of VITEK® REVEAL™. J Antimicrob Chemother. 2024; 79(9):2237-2245. DOI: 10.1093/jac/dkae219. View

Bartoletti M, Antonelli A, Bussini L, Corcione S, Giacobbe D, Marconi L . Clinical consequences of very major errors with semi-automated testing systems for antimicrobial susceptibility of carbapenem-resistant Enterobacterales. Clin Microbiol Infect. 2022; 28(9):1290.e1-1290.e4. DOI: 10.1016/j.cmi.2022.03.013. View

Yusuf E, Schijffelen M, Leeflang M . How to verify and validate a clinical microbiology test before it can be used in routine diagnostics: a practical guide. Clin Microbiol Infect. 2024; 30(10):1261-1269. DOI: 10.1016/j.cmi.2024.06.028. View

10.

Calvo M, Maugeri G, Migliorisi G, Scalia G, Stefani S . The volatile organic compounds detection in MDR Gram-negatives antimicrobial susceptibility testing: Results from a four-month laboratory experience. Diagn Microbiol Infect Dis. 2024; 110(4):116533. DOI: 10.1016/j.diagmicrobio.2024.116533. View

11.

van Belkum A, Burnham C, Rossen J, Mallard F, Rochas O, Dunne Jr W . Innovative and rapid antimicrobial susceptibility testing systems. Nat Rev Microbiol. 2020; 18(5):299-311. DOI: 10.1038/s41579-020-0327-x. View

12.

Magiorakos A, Srinivasan A, Carey R, Carmeli Y, Falagas M, Giske C . Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance. Clin Microbiol Infect. 2011; 18(3):268-81. DOI: 10.1111/j.1469-0691.2011.03570.x. View

13.

Kuil S, Hidad S, Schneeberger C, Singh P, Rhodes P, de Jong M . Susceptibility Testing by Volatile Organic Compound Detection Direct from Positive Blood Cultures: A Proof-of-Principle Laboratory Study. Antibiotics (Basel). 2022; 11(6). PMC: 9220186. DOI: 10.3390/antibiotics11060705. View

14.

Van Heuverswyn J, Valik J, van der Werff S, Hedberg P, Giske C, Naucler P . Association Between Time to Appropriate Antimicrobial Treatment and 30-day Mortality in Patients With Bloodstream Infections: A Retrospective Cohort Study. Clin Infect Dis. 2022; 76(3):469-478. PMC: 9907509. DOI: 10.1093/cid/ciac727. View

15.

Couchot J, Fournier D, Bour M, Rajeev L, Rhodes P, Singh P . Evaluation of the Reveal® rapid AST system to assess the susceptibility of Pseudomonas aeruginosa from blood cultures. Eur J Clin Microbiol Infect Dis. 2023; 42(3):359-363. DOI: 10.1007/s10096-023-04556-2. View

16.

Yuceel-Timur I, Thierry E, Chainier D, Ndao I, Labrousse M, Grelaud C . Retrospective evaluation of rapid genotypic ID and phenotypic AST systems on positive blood culture turnaround time and simulated potential impacts on bloodstream infection management. J Antimicrob Chemother. 2024; 79(Supplement_1):i26-i31. PMC: 11412238. DOI: 10.1093/jac/dkae280. View

17.

Tibbetts R, George S, Burwell R, Rajeev L, Rhodes P, Singh P . Performance of the Reveal Rapid Antibiotic Susceptibility Testing System on Gram-Negative Blood Cultures at a Large Urban Hospital. J Clin Microbiol. 2022; 60(6):e0009822. PMC: 9199398. DOI: 10.1128/jcm.00098-22. View

18.

Bruins M, Bloembergen P, Ruijs G, Wolfhagen M . Identification and susceptibility testing of Enterobacteriaceae and Pseudomonas aeruginosa by direct inoculation from positive BACTEC blood culture bottles into Vitek 2. J Clin Microbiol. 2004; 42(1):7-11. PMC: 321735. DOI: 10.1128/JCM.42.1.7-11.2004. View